[키움 미국전략/주식 김승혁]

🌏US Daily (9/22) (9/21 종가기준) - 주요 지수 수익률 S&P500 7,764.70 / 1.49% NASDAQ 종합 27,122.09 / 2.26% 다우산업 52,048.83 / 0.71% 러셀2000 2,875.36 / 0.52% 필라델피아 반도체 12,433.17 / 4.29% - 섹터별 수익률 High 3: 엔터/미디어 (4.25%), 반도체 및 장비 (3.60%), 자동차 및 부품 (2.80%) Low 3: 에너지 (-2.57%), 보험 (-1.09%), 운송 (-1.09%) - 세부 업종별 수익률 엔터/미디어 4.25% 반도체 및 장비 3.60% 자동차 및 부품 2.80% 소프트웨어 1.81% 유통 1.38% 내구소비재/의류 1.31% 하드웨어 1.23% 부동산 1.01% 제약 0.92% 자본재 0.78% 은행 0.75% 금융 0.40% 호텔/레저 0.36% 식료품 0.31% 헬스케어 0.17% 가정용품 -0.17% 소재 -0.19% 통신 -0.39% 유틸리티 -0.43% 상업 및 전문서비스 -0.79% 음식료 및 담배 -1.01% 운송 -1.09% 보험 -1.09% - 종목별 수익률 High 3: AKAM (12.33%), MRNA (12.27%), INTC (12.14%) Low 3: MPC (-5.30%), VLO (-4.84%), UPS (-4.35%) - 팩터별 수익률 Momentum 2.11% Growth 2.22% Quality 1.22% High Dividend -0.18% Low Votality -0.40% Enhanced value -0.45% Value 0.61% High Beta 2.87% - 주요 뉴스 ▶ AMD joins $1 trillion club as chipmakers rally on AI-driven demand https://www.reuters.com/business/amd-becomes-latest-chipmaker-reach-1-trillion-valuation-ai-demand-2026-09-21/ ▶ Rare earths force Trump to be less hostile before Xi summit https://www.reuters.com/world/china/rare-earths-force-trump-be-less-hostile-before-xi-summit-2026-09-21/ ▶ Nvidia, QIA-backed Iambic Therapeutics files for US IPO as biotech boom rolls on https://www.reuters.com/legal/litigation/nvidia-qia-backed-iambic-therapeutics-files-us-ipo-biotech-boom-rolls-2026-09-21/ ▶ Scott Bessent, He Lifeng launch talks on AI, trade and critical minerals https://www.reuters.com/business/finance/us-treasurys-bessent-chinas-he-launch-talks-ai-trade-critical-minerals-2026-09-20/ ▶ Google opens pre-orders for $899 Googlebook laptops built around Gemini AI https://www.reuters.com/business/retail-consumer/google-opens-pre-orders-899-googlebook-laptops-built-around-gemini-ai-2026-09-21/ ▶ Aerospace suppliers test rare-earth alternatives to ease reliance on China https://www.reuters.com/business/aerospace-defense/aerospace-suppliers-test-rare-earth-alternatives-ease-reliance-china-2026-09-21/ ▶ Novo says CagriSema shows greater weight loss than Lilly rival in diabetes patients https://www.reuters.com/business/healthcare-pharmaceuticals/novo-says-its-next-gen-obesity-drug-tops-lilly-rival-late-stage-study-2026-09-21/ ▶ Smart ring maker Oura eyes $15.6 billion IPO valuation in fall listings demand test https://www.reuters.com/legal/transactional/smart-ring-maker-oura-shareholders-look-raise-up-22-billion-us-ipo-2026-09-21/